Balanced news tone
News Sentiment
SPRB sentiment intelligence
Spruce Biosciences, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
-13.0% over one week, -16.8% over four weeks, trend inactive, and below fair value.
SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 19:41
- Source
- Stocktwits
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 16 Jul 2026 18:18
- Source
- Stocktwits
B. Riley Securities Initiates Spruce Biosciences(SPRB.US) With Buy Rating, Announces Target Price $160
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 13 Jul 2026 15:31
- Source
- Moomoo
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
B. Riley Initiates Spruce Biosciences at Buy With $160 Price Target
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 13 Jul 2026 12:28
- Source
- MT Newswires
Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 13 Jul 2026 09:24
- Source
- DirectorsTalk Interviews
B.Riley initiates Spruce Biosciences stock with buy rating on therapy potential
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 13 Jul 2026 07:30
- Source
- Investing.com
Spruce Biosciences (SPRB) CEO adds 266 shares through employee stock purchase plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 20:15
- Source
- Stock Titan
Spruce Biosciences CEO to speak at B. Riley healthcare summit
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 20:04
- Source
- Stock Titan
Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 20:01
- Source
- Business Wire
Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 04 Jul 2026 07:00
- Source
- timothysykes.com
Spruce Biosciences Joins the Russell 3000® Index
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 12:00
- Source
- Business Wire
ETFs Investing in Spruce Biosciences, Inc. Stocks
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 05:29
- Source
- TradingView
Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 12:00
- Source
- Business Wire
Spruce Biosciences taps rare-disease doctor for TA-ERT launch prep
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Stock Titan
Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 12:00
- Source
- Business Wire
Spruce Biosciences Reports Long-Term Data for Enzyme Replacement Therapy to Treat Genetic Disease MPS IIIB
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 21:45
- Source
- MT Newswires
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 20:05
- Source
- Business Wire
UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+
- Tone
- Positive 84/100
- Event
- Earnings
- Published
- 26 May 2026 07:00
- Source
- eciks.org
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- BioSpace
$SPRB ($SPRB) Releases Q1 2026 Earnings | SPRB Stock News
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- Quiver Quantitative
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Spruce adds two rare-disease launch veterans before potential TA-ERT rollout
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 May 2026 07:00
- Source
- Stock Titan
GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2026 07:00
- Source
- StockStory
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Why Is Spruce Biosciences Stock Sinking Tuesday?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Apr 2026 07:00
- Source
- Benzinga